Dongfang Meng

This inventor holds 23 USPTO granted patents and 3 published patent applications, plus 3 CIPO patents and 13 EPO patents, primarily in Pharmaceutical Compounds. Top assignees: Merck Sharp + Dohme Corp., Merck + Co., Inc., Sloan-Kettering Institute for Cancer Research. Active years: 2004-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Dongfang Meng. Retrieved from https://idiyas.com/inventor/dongfang-meng

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 3)

% Patents Active = 78.3

CIPO Patents = 3 (Patent Applications = 3)

EPO Patents = 13 (Patent Applications = 11)

Average Co-Inventor Count = 5.9

ph-index = 4

Forward Citations = 42(Granted Patents)

Location History:

New York, NY (US) (2005)
Westfield, NJ (US) (2004 - 2014)
Morganville, NJ (US) (2017 - 2021)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Sloan-Kettering Institute for Cancer Research

patents

4. 1 out of 1

Mochida Paraceuticals Co., Ltd.

where one patent can have more than one assignee

Years Active: 2004-2025

Loading Chart...

Areas of Expertise:

PDE9 Inhibitors

TrkA Kinase Inhibitors

Estrogen Receptor Modulators

Antifungal Agents

Nargenicin Compounds

Hydroxylamine Derivatives

Factor IXa Inhibitors

Epothilones

Selective Estrogen Receptor Modulators

Compositions

Methods

Synthesis

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12247031 - Cyclobutyl pyrazolopyrimidine PDE9 inhibitors (2025-03-11),

2. 11028092 - Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors (2021-06-08),

3. 10934294 - Substituted pyrazolo[3,4-d]pyrimidines as PDE9 inhibitors (2021-03-02),

4. 10556900 - TrkA kinase inhibitors, compositions and methods thereof (2020-02-11),

5. 10472345 - Methods of preparing hydroxylamine derivatives useful in the preparation of anti-infective agents (2019-11-12),

6. 10351558 - Factor IXa inhibitors (2019-07-16),

7. 10189819 - Factor IXa inhibitors (2019-01-29),

8. 10144741 - Nargenicin compounds and uses thereof as antibacterial agents (2018-12-04),

9. 9944654 - Nargenicin compounds and uses thereof as antibacterial agents (2018-04-17),

10. 9815846 - TrkA kinase inhibitors, compositions and methods thereof (2017-11-14),

11. 8722727 - Antifungal agents (2014-05-13),

12. 8481575 - Synthesis of epothilones, intermediates thereto, analogues and uses thereof (2013-07-09),

13. 8188085 - Antifungal agents (2012-05-29),

14. 7923568 - Estrogen receptor modulators (2011-04-12),

15. 7863465 - Antifungal agents (2011-01-04),

Title: Dongfang Meng: Pioneering Inventor from Westfield, NJ

Introduction: Dongfang Meng is a highly accomplished inventor based in Westfield, NJ, known for his groundbreaking innovations in various fields.

Latest Patents: Dongfang Meng holds several patents in the areas of renewable energy technologies, advanced materials, and medical devices, showcasing his diverse expertise and creativity.

Career Highlights: With over two decades of experience in the innovation industry, Dongfang Meng has worked with leading research institutions and companies to develop cutting-edge solutions that have made a significant impact on society.

Collaborations: Throughout his career, Dongfang Meng has collaborated with top scientists, engineers, and inventors globally, fostering a culture of innovation and excellence in all his projects.

Conclusion: Dongfang Meng's relentless pursuit of innovation and his passion for creating solutions to complex challenges have solidified his reputation as a pioneering inventor in Westfield, NJ, and beyond.

Profile summary based on public USPTO records.